Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma
出版年份 2017 全文链接
标题
Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma
作者
关键词
-
出版物
INTERNATIONAL IMMUNOLOGY
Volume 30, Issue 1, Pages 13-22
出版商
Oxford University Press (OUP)
发表日期
2017-12-23
DOI
10.1093/intimm/dxx073
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Therapy in Melanoma
- (2016) Margaret K. Callahan CANCER JOURNAL
- Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
- (2016) David Cella et al. LANCET ONCOLOGY
- Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
- (2016) Ran He et al. NATURE
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pro- and anti-apoptotic CD95 signaling in T cells
- (2011) Maren Paulsen et al. Cell Communication and Signaling
- Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature
- (2011) Pawel Muranski et al. IMMUNITY
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
- (2011) S. C. Bendall et al. SCIENCE
- Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice
- (2010) X. Wang et al. BLOOD
- Adoptive Therapy Using Antigen-Specific T-Cell Clones
- (2010) Cassian Yee CANCER JOURNAL
- Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity
- (2010) Sung P. Ha et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Naive tumor-specific CD4+T cells differentiated in vivo eradicate established melanoma
- (2010) Ying Xie et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
- (2010) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase
- (2010) T. L. Frankel et al. JOURNAL OF IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Adoptive immunotherapy of cancer using CD4+ T cells
- (2009) Pawel Muranski et al. CURRENT OPINION IN IMMUNOLOGY
- T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
- (2009) Natalia Martin-Orozco et al. IMMUNITY
- Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells
- (2008) Michael G. Kattah et al. ARTHRITIS AND RHEUMATISM
- Tumor-specific Th17-polarized cells eradicate large established melanoma
- (2008) P. Muranski et al. BLOOD
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
- (2008) Carolina Berger et al. JOURNAL OF CLINICAL INVESTIGATION
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
- (2008) Naomi N. Hunder et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started